Cargando…

Immunological biomarkers predict HIV-1 viral rebound after treatment interruption

Treatment of HIV-1 infection with antiretroviral therapy (ART) in the weeks following transmission may induce a state of ‘post-treatment control' (PTC) in some patients, in whom viraemia remains undetectable when ART is stopped. Explaining PTC could help our understanding of the processes that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hurst, Jacob, Hoffmann, Matthias, Pace, Matthew, Williams, James P., Thornhill, John, Hamlyn, Elizabeth, Meyerowitz, Jodi, Willberg, Chris, Koelsch, Kersten K., Robinson, Nicola, Brown, Helen, Fisher, Martin, Kinloch, Sabine, Cooper, David A., Schechter, Mauro, Tambussi, Giuseppe, Fidler, Sarah, Babiker, Abdel, Weber, Jonathan, Kelleher, Anthony D., Phillips, Rodney E., Frater, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Pub. Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633715/ https://www.ncbi.nlm.nih.gov/pubmed/26449164 http://dx.doi.org/10.1038/ncomms9495

Ejemplares similares

Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruption
por: Pace, Matthew, et al.
Publicado: (2022)

HIV-1 DNA predicts disease progression and post-treatment virological control
por: Williams, James P, et al.
Publicado: (2014)

Plasma HIV Viral Rebound following Protocol-Indicated Cessation of ART Commenced in Primary and Chronic HIV Infection
por: Hamlyn, Elizabeth, et al.
Publicado: (2012)

Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection
por: Hoffmann, Matthias, et al.
Publicado: (2016)

Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound
por: Zacharopoulou, P., et al.
Publicado: (2022)

Levels of Human Immunodeficiency Virus DNA Are Determined Before ART Initiation and Linked to CD8 T-Cell Activation and Memory Expansion
por: Martin, Genevieve E, et al.
Publicado: (2020)

A pilot evaluation of whole blood finger-prick sampling for point-of-care HIV viral load measurement: the UNICORN study
por: Fidler, Sarah, et al.
Publicado: (2017)

Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy
por: Stöhr, Wolfgang, et al.
Publicado: (2013)

CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA
por: Martin, Genevieve E., et al.
Publicado: (2018)

Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral Therapy
por: Martin, Genevieve E., et al.
Publicado: (2021)

Tolerability of four‐drug antiretroviral combination therapy in primary HIV‐1 infection
por: Burns, JE, et al.
Publicado: (2021)

Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection
por: Thornhill, John, et al.
Publicado: (2014)

Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort
por: Granger, Luke A., et al.
Publicado: (2021)

The Role of CD4+ T Follicular Helper Cells in HIV Infection: From the Germinal Center to the Periphery
por: Thornhill, John Patrick, et al.
Publicado: (2017)

Maintenance of Functional CD57+ Cytolytic CD4+ T Cells in HIV+ Elite Controllers
por: Phetsouphanh, Chansavath, et al.
Publicado: (2019)

Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption
por: Giron, Leila B., et al.
Publicado: (2021)

Human MAIT cells respond to and suppress HIV-1
por: Phetsouphanh, Chansavath, et al.
Publicado: (2021)

Brief Report: Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection
por: Thornhill, John, et al.
Publicado: (2016)

Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection
por: Martin, Genevieve E., et al.
Publicado: (2017)

Compartmentalized HIV rebound in the central nervous system after interruption of antiretroviral therapy
por: Gianella, Sara, et al.
Publicado: (2016)

Models of SIV rebound after treatment interruption that involve multiple reactivation events
por: van Dorp, Christiaan H., et al.
Publicado: (2020)

Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption
por: Park, You Jeong, et al.
Publicado: (2017)

To rebound or not to rebound
por: Stahl, Bethany A, et al.
Publicado: (2017)

Human endogenous retrovirus (HERV) expression is not induced by treatment with the histone deacetylase (HDAC) inhibitors in cellular models of HIV-1 latency
por: Hurst, Tara, et al.
Publicado: (2016)

Structured Observations Reveal Slow HIV-1 CTL Escape
por: Roberts, Hannah E., et al.
Publicado: (2015)

HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper
por: Fidler, S., et al.
Publicado: (2020)

Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV
por: Hill, Alison L., et al.
Publicado: (2016)

Dynamics and origin of rebound viremia in SHIV-infected infant macaques following interruption of long-term ART
por: Obregon-Perko, Veronica, et al.
Publicado: (2021)

Divergent Expression of CXCR5 and CCR5 on CD4(+) T Cells and the Paradoxical Accumulation of T Follicular Helper Cells during HIV Infection
por: Zaunders, John, et al.
Publicado: (2017)

Relationship between intact HIV-1 proviruses in circulating CD4(+) T cells and rebound viruses emerging during treatment interruption
por: Lu, Ching-Lan, et al.
Publicado: (2018)

Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV
por: Hill, Alison L., et al.
Publicado: (2017)

Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV
Publicado: (2016)

Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment
por: Aamer, Hadega A., et al.
Publicado: (2020)

Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection
por: Fidler, Sarah, et al.
Publicado: (2017)

Not All Missed Doses Are the Same: Sustained NNRTI Treatment Interruptions Predict HIV Rebound at Low-to-Moderate Adherence Levels
por: Parienti, Jean-Jacques, et al.
Publicado: (2008)

The Effect of HIV Treatment Interruption on Subsequent Immunological Response
por: Thomadakis, Christos, et al.
Publicado: (2023)

COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
por: Epling, Brian P., et al.
Publicado: (2022)

To reuse or not reuse? That is a rebound question!
por: Akkara, John D, et al.
Publicado: (2023)

Low copy target detection by Droplet Digital PCR through application of a novel open access bioinformatic pipeline, ‘definetherain’
por: Jones, Mathew, et al.
Publicado: (2014)

TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption
por: Hsu, Denise C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_npho8uhqjo6nfg0puijmbuf6au